AXSM Axsome Therapeutics Inc

Price (delayed)

$64.84

Market cap

$2.44B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.67

Enterprise value

$2.32B

Highlights
The net income has contracted by 11% YoY but it has grown by 3.1% from the previous quarter
The EPS has contracted by 3.9% YoY but it has grown by 3.6% from the previous quarter
Axsome Therapeutics's debt has surged by 149% YoY
The equity has declined by 38% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
37.57M
Market cap
$2.44B
Enterprise value
$2.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
25.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$95.74M
EBITDA
-$95.4M
Free cash flow
-$82.47M
Per share
EPS
-$2.67
Free cash flow per share
-$2.2
Book value per share
$2.57
Revenue per share
$0
TBVPS
$4.46
Balance sheet
Total assets
$166.9M
Total liabilities
$70.61M
Debt
$50.12M
Equity
$96.29M
Working capital
$143.35M
Liquidity
Debt to equity
0.52
Current ratio
7.61
Quick ratio
7.59
Net debt/EBITDA
1.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.3%
Return on equity
-79.8%
Return on invested capital
-444.4%
Return on capital employed
-65.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
-3.53%
1 week
2.11%
1 month
10.99%
1 year
-15.3%
YTD
-20.41%
QTD
14.52%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$94.49M
Net income
-$99.68M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 11% YoY but it has grown by 3.1% from the previous quarter
The company's operating income fell by 6% YoY but it rose by 4.7% QoQ

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
25.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 3.9% YoY but it has grown by 3.6% from the previous quarter
The equity has declined by 38% year-on-year and by 15% since the previous quarter
The P/B is 19% higher than the last 4 quarters average of 22.0 but 6% lower than the 5-year quarterly average of 27.7

Efficiency

How efficient is Axsome Therapeutics business performance
The company's return on invested capital has surged by 100% YoY and by 45% QoQ
AXSM's ROA is up by 24% YoY
The ROE has grown by 19% YoY but it has contracted by 8% from the previous quarter

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 136% more than its total liabilities
AXSM's total liabilities has soared by 70% year-on-year but it is down by 2.4% since the previous quarter
Axsome Therapeutics's total assets has decreased by 16% YoY and by 10% from the previous quarter
Axsome Therapeutics's debt is 48% lower than its equity
Axsome Therapeutics's debt has surged by 149% YoY
The equity has declined by 38% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.